Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly for treating obesity and type 2 diabetes. It is taken once daily by mouth without food or water restrictions and has been shown to reduce blood sugar levels and body weight effectively, with a safety profile similar to other GLP-1 agonists. It is grouped under the following drug class(es): GLP‑1 Receptor Agonists. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include GLP-1 receptor agonist 1, 1, 2, 4-Oxadiazol-5(2H)-one, 3-[(1S, 2S)-1-[2-[[(4S)-2-(4-fluoro-3, 5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2, 3-dihydro-2-oxo-1H-imidazol-1-yl]-2, 4, 6, 7-tetrahydro-4-methyl-5H-pyrazolo[4, 3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2 and 2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcyclopropyl]-. Its PubChem CID is 137319706.
Orforglipron
| CAS No | 2212020-52-3 |
|---|---|
| Molecular Formula | C48H48F2N10O5 |
| Molecular Weight | 883.0 g/mol |
| Synonyms | 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist developed by Eli Lilly for treating obesity and type 2 diabetes.
The listed CAS number is 2212020-52-3.
The listed molecular formula is C48H48F2N10O5.
The listed molecular weight is 883.0 g/mol.
3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one.
The source lists GLP-1 receptor agonist 1, 1, 2, 4-Oxadiazol-5(2H)-one, 3-[(1S, 2S)-1-[2-[[(4S)-2-(4-fluoro-3, 5-dimethylphenyl)-3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2, 3-dihydro-2-oxo-1H-imidazol-1-yl]-2, 4, 6, 7-tetrahydro-4-methyl-5H-pyrazolo[4, 3-c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2 and 2-dimethyl-2H-pyran-4-yl]-1H-indol-1-yl]-2-methylcyclopropyl]-.